{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The expression/levels and response will be evaluated using logistic regression models.","groups":[{"description":"Patients receive abatacept IV over 30 minutes on day 1 of course 1, then SC on days 2, 8, 15, and 22 of course 1, and then on days 1, 8, 15, and 22 of subsequent courses. Patients also receive ixazomib citrate PO QD on days 1, 8, and 15 and dexamethasone on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAbatacept: Given IV and SC\n\nDexamethasone: Given PO\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Treatment (Abatacept, Ixazomib Citrate, Dexamethasone)"}],"populationDescription":"These measurements were not collected and are not available for reporting.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"CD28 and CD86 Expression Assessed by Flow Cytometry","type":"OTHER_PRE_SPECIFIED"}